Figure 2:
Optimization of light dosage for immune priming.
(A) Dual subcutaneous AE17-OVA+ tumor bearing mice were treated with either PBS or PLP (4 mg/kg). Twenty-four hours post-injection, the left hindlimb tumors on mice were irradiated with a 671 nm laser at a light dose of either 25 J/cm2, 50 J/cm2, or 75 J/cm2. Evaluation of tumor volumes of irradiated left hindlimb tumor volumes (n = 5). (B) Assessment of non-irradiated right hindlimb tumor volumes (n = 5). (C) Survival of mice treated with either PBS + 75 J/cm2, PLP + 25 J/cm2, PLP + 50 J/cm2, or PLP + 75 J/cm2 (n = 5). (D) Histological analysis of the percentage of CD3+ T cells in spleens of mice harvested at time of endpoint (n = 3). (E) Microscopic image of a CD3-stained spleen from one mouse in each treatment group. Data are mean ± standard deviation. Statistical significance was determined using a one-way ANOVA followed by a post-hoc Tukey test. *p < 0.05, **p < 0.01.